Applications of cellular systems biology in breast cancer patient stratification and diagnostics

Combinatorial Chemistry and High Throughput Screening

Volumn 12, Issue 9, 2009, Pages 860-869

  Critchley Thorne, Rebecca J ^a   Miller, Steven M ^b   Taylor, D Lansing ^a   Lingle, Wilma L ^b  

^a Cellumen Inc   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Biomarkers; Breast cancer; Cellular systems biology; Diagnostics; Tissue microarrays

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MAMMAGLOBIN; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER RESEARCH; CANCER RISK; CANCER TEST; CELL ASSAY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMS BIOLOGY; TISSUE DISTRIBUTION; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; SENSITIVITY AND SPECIFICITY; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 70349461805     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620709789383222     Document Type: Review

References (127)

1. Guiliano, K.A.; Premkumar, D.; Strock, C.J.; Johnston, P.; Taylor, D.L. Cellular systems biology profiling applied to cellular models of disease. Comb Chem High Throughput Screen 2009, 12(9), 838-847.
2. Vernetti, L.; Irwin, W.; Giuliano, K.; Gough, A.; Taylor, D.L. Cellular Systems Biology applied to pre-clinical safety testing: A case study of CellCiphr profiling. In Drug Efficacy, Safety and Biologics Discovery: Emerging Technologies and Tools; Xu, J. J.; Ekins, S., Eds.; Wiley & Sons: New Jersey, 2008; In Press.
3. O'Sullivan, C.; Lewis, C.E.; Harris, A.L.; McGee, J.O. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993, 342(8864), 148-149. (Pubitemid 23200443)
4. Khorana, A.A.; Ryan, C. K.; Cox, C.; Eberly, S.; Sahasrabudhe, D.M. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer, 2003, 97(4), 960-968.
5. Lewis, J.S.; Landers, R.J.; Underwood, J.C.; Harris, A.L.; Lewis, C.E., Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol., 2000, 192(2), 150-158.
6. Leek, R.D.; Lewis, C.E.; Whitehouse, R.; Greenall, M.; Clarke, J.; Harris, A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res., 1996, 56(20), 4625-4629.
7. Schoppmann, S.F.; Fenzl, A.; Nagy, K.; Unger, S.; Bayer, G.; Geleff, S.; Gnant, M.; Horvat, R.; Jakesz, R.; Birner, P. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery, 2006, 139(6), 839-846. (Pubitemid 43902914)
8. Bingle, L.; Brown, N.J.; Lewis, C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 2002, 196(3), 254-265.
9. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3), 161-174. (Pubitemid 37328786)
10. Hagemann, T.; Robinson, S.C.; Schulz, M.; Trumper, L.; Balkwill, F.R.; Binder, C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis, 2004, 25(8), 1543-1549. (Pubitemid 39162720)
11. Sica, A.; Saccani, A.; Bottazzi, B.; Polentarutti, N.; Vecchi, A.; van Damme, J.; Mantovani, A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol., 2000, 164(2), 762-767. (Pubitemid 30043699)
12. Klimp, A.H.; Hollema, H.; Kempinga, C.; van der Zee, A.G.; de Vries, E.G.; Daemen, T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res., 2001, 61(19), 7305-7309. (Pubitemid 32946529)
13. Allavena, P.; Sica, A.; Solinas, G.; Porta, C.; Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol., 2008, 6(1), 1-9. (Pubitemid 351324128)
14. Liyanage, U.K.; Moore, T.T.; Joo, H.G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J. A.; Strasberg, S.M.; Eberlein, T.J.; Goedegebuure, P.S.; Linehan, D.C. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol., 2002, 169(5), 2756-2761.
15. Matsuura, K.; Yamaguchi, Y.; Ueno, H.; Osaki, A.; Arihiro, K.; Toge, T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer, 2006, 106(6), 1227-1236. (Pubitemid 43363898)
16. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol., 2006, 6(4), 295-307.
17. Schutyser, E.; Struyf, S.; Proost, P.; Opdenakker, G.; Laureys, G.; Verhasselt, B.; Peperstraete, L.; Van de Putte, I.; Saccani, A.; Allavena, P.; Mantovani, A.; Van Damme, J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem., 2002, 277(27), 24584-24593. (Pubitemid 34951986)
18. Adema, G.J.; Hartgers, F.; Verstraten, R.; de Vries, E.; Marland, G.; Menon, S.; Foster, J.; Xu, Y.; Nooyen, P.; McClanahan, T.; Bacon, K.B.; Figdor, C.G. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature, 1997, 387(6634), 713-717.
19. Milliken, D.; Scotton, C.; Raju, S.; Balkwill, F.; Wilson, J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer. Res., 2002, 8(4), 1108-1114. (Pubitemid 35177363)
20. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4(7), 540-550.
21. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer. Biol., 2006, 16(1), 53-65. (Pubitemid 43139709)
22. Huang, B.; Pan, P. Y.; Li, Q.; Sato, A. I.; Levy, D. E.; Bromberg, J.; Divino, C. M.; Chen, S. H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res., 2006, 66(2), 1123-1131.
23. Wei, S.; Kryczek, I.; Zou, L.; Daniel, B.; Cheng, P.; Mottram, P.; Curiel, T.; Lange, A.; Zou, W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer. Res., 2005, 65(12), 5020-5026. (Pubitemid 40827308)
24. Ghiringhelli, F.; Puig, P.E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGF-beta- secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med., 2005, 202(7), 919-929. (Pubitemid 41396892)
25. Zippelius, A.; Batard, P.; Rubio-Godoy, V.; Bioley, G.; Lienard, D.; Lejeune, F.; Rimoldi, D.; Guillaume, P.; Meidenbauer, N.; Mackensen, A.; Rufer, N.; Lubenow, N.; Speiser, D.; Cerottini, J.C.; Romero, P.; Pittet, M.J. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res., 2004, 64(8), 2865-2873.
26. Cheng, B. Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer. J. Huazhong. Univ. Sci. Technol. Med. Sci., 2006, 26(5), 573-575.
27. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle, 2006, 5(15), 1597-1601.
28. Moinfar, F.; Man, Y.G.; Arnould, L.; Bratthauer, G.L.; Ratschek, M.; Tavassoli, F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer. Res., 2000, 60(9), 2562-2566
29. Lindmark, G.; Sundberg, C.; Glimelius, B.; Pahlman, L.; Rubin, K.; Gerdin, B. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab. Invest., 1993, 69(6), 682-689. (Pubitemid 24026849)
30. Coltrera, M.D.; Wang, J.; Porter, P.L.; Gown, A.M. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res., 1995, 55(12), 2703-2708.
31. Bhardwaj, B.; Klassen, J.; Cossette, N.; Sterns, E.; Tuck, A.; Deeley, R.; Sengupta, S.; Elliott, B. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin. Cancer Res., 1996, 2(4), 773-782. (Pubitemid 26135343)
32. Benson, J.R.; Wakefield, L.M.; Baum, M.; Colletta, A.A. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. Br. J. Cancer, 1996, 74(3), 352-358.
33. Rosenthal, E.; McCrory, A.; Talbert, M.; Young, G.; Murphy- Ullrich, J.; Gladson, C. Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol. Carcinog., 2004, 40(2), 116-121. (Pubitemid 38736537)
34. Singer, C.F.; Kronsteiner, N.; Marton, E.; Kubista, M.; Cullen, K.J.; Hirtenlehner, K.; Seifert, M.; Kubista, E., MMP-2 and MMP- 9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast. Cancer. Res. Treat., 2002, 72(1), 69-77. (Pubitemid 34274316)
35. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 2005, 121(3), 335-348.
36. O'Neill, J.S.; Miller, W.R. Aromatase activity in breast adipose tissue from women with benign and malignant breast diseases. Br. J. Cancer, 1987, 56(5), 601-604.
37. Santner, S.J.; Pauley, R.J.; Tait, L.; Kaseta, J.; Santen, R.J., Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J. Clin. Endocrinol. Metab., 1997, 82(1), 200-208. (Pubitemid 27021297)
38. Zhou, J.; Gurates, B.; Yang, S.; Sebastian, S.; Bulun, S.E., Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res., 2001, 61(5), 2328-2334.
39. Hudelist, G.; Wulfing, P.; Kersting, C.; Burger, H.; Mattsson, B.; Czerwenka, K.; Kubista, E.; Gschwantler-Kaulich, D.; Fink-Retter, A.; Singer, C.F. Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. J. Cancer Res. Clin. Oncol., 2008, 134(1), 67-73. (Pubitemid 350060686)
40. Farnsworth, R.H.; Achen, M.G.; Stacker, S.A. Lymphatic endothelium: an important interactive surface for malignant cells. Pulm. Pharmacol. Ther., 2006, 19(1), 51-60.
41. Witz, I. P. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat. Res., 2006, 130, 125-140.
42. Entschladen, F.; Palm, D.; Lang, K.; Drell, T. L. t.; Zaenker, K. S. Neoneurogenesis: tumors may initiate their own innervation by the release of neurotrophic factors in analogy to lymphangiogenesis and neoangiogenesis. Med. Hypotheses, 2006, 67(1), 33-35.
43. Entschladen, F.; Palm, D.; Drell, T.L.t.; Lang, K.; Zaenker, K.S. Connecting a tumor to the environment. Curr. Pharm. Des., 2007, 13(33), 3440-3444.
44. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25(33), 5287-5312.
45. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N. Engl. J. Med., 2004, 351(27), 2817-2826. (Pubitemid 40051905)
46. Paik, S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist, 2007, 12(6), 631-635.
47. Sparano, J. A. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer, 2006, 7(4), 347-350.
48. van de Vijver, M.J.; He, Y.D.; van't Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; Parrish, M.; Atsma, D.; Witteveen, A.; Glas, A.; Delahaye, L.; van der Velde, T.; Bartelink, H.; Rodenhuis, S.; Rutgers, E.T.; Friend, S.H.; Bernards, R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347(25), 1999-2009.
49. Mook, S.; Van't Veer, L. J.; Rutgers, E. J.; Piccart-Gebhart, M. J.; Cardoso, F. Individualization of therapy using mammaprint: from development to the MINDACT trial. Cancer Genomics Proteomics, 2007, 4(3), 147-155.
50. Blumencranz, P.; Whitworth, P.W.; Deck, K.; Rosenberg, A.; Reintgen, D.; Beitsch, P.; Chagpar, A.; Julian, T.; Saha, S.; Mamounas, E.; Giuliano, A.; Simmons, R. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am. J. Surg., 2007, 194(4), 426-432.
51. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.; Hayes, D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med., 2004, 351(8), 781-791. (Pubitemid 39095313)
52. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M.J., Cancer statistics, 2007. CA Cancer J. Clin., 2007, 57(1), 43-66.
53. Kersh, E.N.; Shaw, A.S.; Allen, P.M. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science, 1998, 281(5376), 572-575.
54. Reichert, T.E.; Day, R.; Wagner, E.M.; Whiteside, T.L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res., 1998, 58(23), 5344-5347.
55. Taylor, D.D.; Bender, D.P.; Gercel-Taylor, C.; Stanson, J.; Whiteside, T.L. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br. J. Cancer, 2001, 84(12), 1624-1629.
56. Gastman, B.R.; Atarshi, Y.; Reichert, T.E.; Saito, T.; Balkir, L.; Rabinowich, H.; Whiteside, T.L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res., 1999, 59(20), 5356-5364.
57. Dworacki, G.; Meidenbauer, N.; Kuss, I.; Hoffmann, T.K.; Gooding, W.; Lotze, M.; Whiteside, T.L. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res., 2001, 7(3 Suppl), 947s-957s.
58. Kono, K.; Ressing, M.E.; Brandt, R.M.; Melief, C.J.; Potkul, R.K.; Andersson, B.; Petersson, M.; Kast, W.M.; Kiessling, R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer. Res., 1996, 2(11), 1825-1828. (Pubitemid 26384148)
59. Ezernitchi, A.V.; Vaknin, I.; Cohen-Daniel, L.; Levy, O.; Manaster, E.; Halabi, A.; Pikarsky, E.; Shapira, L.; Baniyash, M. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol., 2006, 177(7), 4763-4772. (Pubitemid 44469811)
60. Groh, V.; Wu, J.; Yee, C.; Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 2002, 419(6908), 734-738. (Pubitemid 35177960)
61. Varker, K.A.; Terrell, C.E.; Welt, M.; Suleiman, S.; Thornton, L.; Andersen, B.L.; Carson, W. E. 3rd, Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J. Surg. Res., 2007, 139(1), 36-44.
62. Madjd, Z.; Spendlove, I.; Moss, R.; Bevin, S.; Pinder, S.E.; Watson, N.F.; Ellis, I.; Durrant, L.G. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun., 2007, 7, 17.
63. Van Laere, S.J.; Van der Auwera, I.; Van den Eynden, G.G.; van Dam, P.; Van Marck, E.A.; Vermeulen, P.B.; Dirix, L.Y. NFkappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br. J. Cancer, 2007, 97(5), 659-669.
64. Wu, J.T.; Kral, J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res., 2005, 123(1), 158-169. (Pubitemid 40094658)
65. Van Waes, C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Cancer Res., 2007, 13(4), 1076-1082. (Pubitemid 46424045)
66. Widschwendter, A.; Tonko-Geymayer, S.; Welte, T.; Daxenbichler, G.; Marth, C.; Doppler, W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res., 2002, 8(10), 3065-3074. (Pubitemid 35155015)
67. Dolled-Filhart, M.; Camp, R.L.; Kowalski, D.P.; Smith, B.L.; Rimm, D.L. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin. Cancer Res., 2003, 9(2), 594-600.
68. Nevalainen, M.T.; Xie, J.; Torhorst, J.; Bubendorf, L.; Haas, P.; Kononen, J.; Sauter, G.; Rui, H., Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J. Clin. Oncol., 2004, 22(11), 2053-2060. (Pubitemid 41095137)
69. de Jong, J.S.; van Diest, P.J.; Baak, J.P. Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br. J. Cancer, 2000, 82(2), 368-373.
70. O'Donovan, N.; Crown, J.; Stunell, H.; Hill, A.D.; McDermott, E.; O'Higgins, N.; Duffy, M. J. Caspase 3 in breast cancer. Clin. Cancer Res., 2003, 9(2), 738-742.
71. Nakopoulou, L.; Alexandrou, P.; Stefanaki, K.; Panayotopoulou, E.; Lazaris, A.C.; Davaris, P.S. Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology, 2001, 69(5), 266-273. (Pubitemid 34762168)
72. Dolled-Filhart, M.; McCabe, A.; Giltnane, J.; Cregger, M.; Camp, R.L.; Rimm, D.L. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res., 2006, 66(10), 5487-5494.
73. Nakopoulou, L.; Mylona, E.; Papadaki, I.; Kavantzas, N.; Giannopoulou, I.; Markaki, S.; Keramopoulos, A. Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod. Pathol., 2006, 19(4), 556-563.
74. Orend, G.; Hunter, T.; Ruoslahti, E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene, 1998, 16(20), 2575-2583. (Pubitemid 28264035)
75. Asada, M.; Yamada, T.; Ichijo, H.; Delia, D.; Miyazono, K.; Fukumuro, K.; Mizutani, S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J., 1999, 18(5), 1223-1234. (Pubitemid 29110307)
76. Zhou, B.P.; Liao, Y.; Xia, W.; Spohn, B.; Lee, M.H.; Hung, M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell. Biol., 2001, 3(3), 245-252.
77. Xia, W.; Chen, J.S.; Zhou, X.; Sun, P.R.; Lee, D.F.; Liao, Y.; Zhou, B.P.; Hung, M.C. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer. Res., 2004, 10(11), 3815-3824.
78. Winters, Z.E.; Leek, R.D.; Bradburn, M.J.; Norbury, C.J.; Harris, A.L. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res., 2003, 5(6), R242-249.
79. Arya, M.; Ahmed, H.; Silhi, N.; Williamson, M.; Patel, H.R. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol., 2007, 28(3), 123-131.
80. Cabioglu, N.; Sahin, A.; Doucet, M.; Yavuz, E.; Igci, A.; E, O.Y.; Aktas, E.; Bilgic, S.; Kiran, B.; Deniz, G.; Price, J.E. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin. Exp. Metastasis, 2005, 22(1), 39-46.
81. Salvucci, O.; Bouchard, A.; Baccarelli, A.; Deschenes, J.; Sauter, G.; Simon, R.; Bianchi, R.; Basik, M., The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat., 2006, 97, (3), 275-283. (Pubitemid 43945757)
82. Wolberg, W.H.; Street, W.N. Computer-generated nuclear features compared with axillary lymph node status and tumor size as indicators of breast cancer survival. Hum. Pathol., 2002, 33(11), 1086-1091. (Pubitemid 35416705)
83. Bell, D.; Chomarat, P.; Broyles, D.; Netto, G.; Harb, G.M.; Lebecque, S.; Valladeau, J.; Davoust, J.; Palucka, K.A.; Banchereau, J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med., 1999, 190(10), 1417-1426.
84. Ladanyi, A.; Kiss, J.; Somlai, B.; Gilde, K.; Fejos, Z.; Mohos, A.; Gaudi, I.; Timar, J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer. Immunol. Immunother., 2007, 56(9), 1459-1469. (Pubitemid 47024707)
85. Wakabayashi, O.; Yamazaki, K.; Oizumi, S.; Hommura, F.; Kinoshita, I.; Ogura, S.; Dosaka-Akita, H.; Nishimura, M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci., 2003, 94(11), 1003-1009. (Pubitemid 37521216)
86. Bates, G.J.; Fox, S.B.; Han, C.; Leek, R.D.; Garcia, J.F.; Harris, A.L.; Banham, A.H. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol., 2006, 24(34), 5373-5380.
87. Sheridan, C.; Kishimoto, H.; Fuchs, R.K.; Mehrotra, S.; Bhat- Nakshatri, P.; Turner, C.H.; Goulet, R., Jr.; Badve, S.; Nakshatri, H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res., 2006, 8(5), R59. (Pubitemid 44804002)
88. Frey, A.B. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest., 2006, 116(10), 2587-2590. (Pubitemid 44511621)
89. Ring, B.Z.; Seitz, R.S.; Beck, R.; Shasteen, W.J.; Tarr, S.M.; Cheang, M.C.; Yoder, B.J.; Budd, G.T.; Nielsen, T.O.; Hicks, D.G.; Estopinal, N.C.; Ross, D.T. Novel prognostic immunohistochemical biomarker panel for estrogen receptorpositive breast cancer. J. Clin. Oncol., 2006, 24(19), 3039-3047.
90. Guo, L.; Abraham, J.; Flynn, D.C.; Castranova, V.; Shi, X.; Qian, Y. Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho- HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phosphop70S6K proteins. Int. J. Biol. Markers, 2007, 22(1), 1-11.
91. Camp, R.L.; Charette, L.A.; Rimm, D.L. Validation of tissue microarray technology in breast carcinoma. Lab. Invest., 2000, 80(12), 1943-1949.
92. Osborne, C.K. Steroid hormone receptors in breast cancer management. Breast, Cancer, Res. Treat, 1998, 51(3), 227-238. (Pubitemid 29054556)
93. Carney, W.P.; Leitzel, K.; Ali, S.; Neumann, R.; Lipton, A.HER- 2/neu diagnostics in breast cancer. Breast Cancer Res., 2007, 9(3), 207.
94. Reimer, T.; Koczan, D.; Muller, H.; Friese, K.; Thiesen, H.J.; Gerber, B. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res., 2002, 4(5), R9.
95. Bebenek, M.; Dus, D.; Kozlak, J. Fas and Fas ligand as prognostic factors in human breast carcinoma. Med. Sci. Monit., 2006, 12(11), CR457-61.
96. McCarthy, M.M.; Sznol, M.; DiVito, K.A.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin. Cancer Res., 2005, 11(14), 5188-5194. (Pubitemid 41003705)
97. Vakkala, M.; Paakko, P.; Soini, Y. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br. J. Cancer, 1999, 81(4), 592-599. (Pubitemid 29458853)
98. Schmitz, K.J.; Grabellus, F.; Callies, R.; Wohlschlaeger, J.; Otterbach, F.; Kimmig, R.; Levkau, B.; Schmid, K.W.; Baba, H.A. Relationship and prognostic significance of phospho-(serine 166)- murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression. Virchows Arch., 2006, 448(1), 16-23.
99. Yamashita, S.; Masuda, Y.; Kurizaki, T.; Haga, Y.; Murayama, T.; Ikei, S.; Kamei, M.; Takeno, S.; Kawahara, K., Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res., 2007, 27(4C), 2803-12508 (Pubitemid 47228001)
100. O'Driscoll, L.; Cronin, D.; Kennedy, S.M.; Purcell, R.; Linehan, R.; Glynn, S.; Larkin, A.; Scanlon, K.; McDermott, E.W.; Hill, A.D.; O'Higgins, N.J.; Parkinson, M.; Clynes, M. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res., 2004, 24(2A), 473-482. (Pubitemid 38623122)
101. Trere, D.; Montanaro, L.; Ceccarelli, C.; Barbieri, S.; Cavrini, G.; Santini, D.; Taffurelli, M.; Derenzini, M. Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann. Oncol., 2007, 18(6), 1004-1014. (Pubitemid 47050491)
102. Thor, A.D.; Moore, D.H., II; Edgerton, S.M.; Kawasaki, E.S.; Reihsaus, E.; Lynch, H.T.; Marcus, J.N.; Schwartz, L.; Chen, L.C.; Mayall, B.H.; et al., Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 1992, 84(11), 845-855
103. Tsutsui, S.; Ohno, S.; Murakam, S.; Hachitanda, Y.; Oda, S. Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer, 2001, 8(3), 194-201.
104. Nohara, T.; Ryo, T.; Iwamoto, S.; Gon, G.; Tanigawa, N., Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology, 2001, 60(1), 94-100. (Pubitemid 32041438)
105. Milde-Langosch, K.; Bamberger, A.M.; Rieck, G.; Kelp, B.; Loning, T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res. Treat., 2001, 67(1), 61-70. (Pubitemid 32703389)
106. Umekita, Y.; Ohi, Y.; Sagara, Y.; Yoshida, H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int. J. Cancer, 2002, 98(3), 415-418. (Pubitemid 34188685)
107. Keyomarsi, K.; Tucker, S.L.; Buchholz, T.A.; Callister, M.; Ding, Y.; Hortobagyi, G.N.; Bedrosian, I.; Knickerbocker, C.; Toyofuku, W.; Lowe, M.; Herliczek, T. W.; Bacus, S.S. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med., 2002, 347(20), 1566-1575.
108. Tsutsui, S.; Yasuda, K.; Suzuki, K.; Takeuchi, H.; Nishizaki, T.; Higashi, H.; Era, S. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br. J. Cancer, 2006, 94(12), 1874-1878. (Pubitemid 43882578)
109. Pick, E.; Kluger, Y.; Giltnane, J.M.; Moeder, C.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res., 2007, 67(7), 2932-2937. (Pubitemid 46724827)
110. Trock, B.J.; Leonessa, F.; Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer. Inst., 1997, 89(13), 917-931. (Pubitemid 27282064)
111. Batist, G.; Tulpule, A.; Sinha, B.K.; Katki, A.G.; Myers, C.E.; Cowan, K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem., 1986, 261(33), 15544-15549.
112. Dittadi, R.; Biganzoli, E.; Boracchi, P.; Salbe, C.; Mione, R.; Gatti, C.; Gion, M. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen. Int. J. Biol. Markers, 1998, 13(1), 30-41. (Pubitemid 28356507)
113. Harigopal, M.; Berger, A.J.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin. Cancer Res., 2005, 11(11), 4083-4089. (Pubitemid 40791572)
114. Morris, S.F.; O'Hanlon, D.M.; McLaughlin, R.; McHale, T.; Connolly, G.E.; Given, H.F. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. Eur. J. Surg. Oncol., 2001, 27(6), 527-531.
115. Bircan, S.; Kapucuoglu, N.; Baspinar, S.; Inan, G.; Candir, O. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol. Res. Pract., 2006, 202(8), 569-576. (Pubitemid 44057770)
116. Morohashi, S.; Kusumi, T.; Sato, F.; Odagiri, H.; Chiba, H.; Yoshihara, S.; Hakamada, K.; Sasaki, M.; Kijima, H. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int. J. Mol. Med., 2007, 20(2), 139-143.
117. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yang, Q.; Imabun, S.; Nakahara, M.; Nakao, K.; Nakamura, M.; Mori, I.; Kakudo, K. Flt- 4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin. Cancer Res., 2003, 9(14), 5313-5317. (Pubitemid 37413585)
118. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yang, Q.; Imabun, S.; Nakahara, M.; Nakao, K.; Nakamura, M.; Mori, I.; Kakudo, K. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin. Cancer Res., 2003, 9(2), 716-721. (Pubitemid 36182605)
119. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yang, Q.; Tsukiyama, A.; Imabun, S.; Nakahara, M.; Nakao, K.; Nakamura, M.; Mori, I.; Kakudo, K. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod. Pathol., 2003, 16(4), 309-314. (Pubitemid 36443979)
120. Chen, H.H.; Su, W.C.; Lin, P.W.; Guo, H. R.; Lee, W.Y. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res. Treat., 2007, 103(2), 167-175. (Pubitemid 46789135)
121. MacGrogan, G.; Jollet, I.; Huet, S.; Sierankowski, G.; Picot, V.; Bonichon, F.; Coindre, J. M. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod. Pathol., 1997, 10(8), 769-776.
122. Schule, J.; Bergkvist, L.; Hakansson, L.; Gustafsson, B.; Hakansson, A. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res. Treat., 2002, 74(1), 33-40. (Pubitemid 34734594)
123. Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattan, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Alshabanah, M.; Bin Amer, S.; Tulbah, A.; Ajarim, D.; Al-Tweigeri, T.; Dermime, S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 2006, 8(3), 190-198. (Pubitemid 43671234)
124. Tsutsui, S.; Yasuda, K.; Suzuki, K.; Tahara, K.; Higashi, H.; Era, S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep., 2005, 14(2), 425-431.
125. Nicolini, A.; Carpi, A.; Rossi, G., Cytokines in breast cancer. Cytokine Growth Factor Rev., 2006, 17(5), 325-337.
126. Zerkowski, M.P.; Camp, R.L.; Burtness, B.A.; Rimm, D.L.; Chung, G.G. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest., 2007, 25(1), 19-26.
127. Kluger, H. M.; Dolled-Filhart, M.; Rodov, S.; Kacinski, B.M.; Camp, R.L.; Rimm, D.L. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin. Cancer. Res., 2004, 10(1 Pt 1), 173-177.